Adcytherix SAS secured a €105 million (approximately $122 million) Series A to advance its lead antibody-drug conjugate program toward clinical development next year. The round positions the Paris-based biotech to enter first-in-human studies and expand preclinical work across its ADC pipeline. The financing reflects investor interest in differentiated payloads and linker technologies and provides Adcytherix with capital to complete IND-enabling studies, GMP manufacturing, and initial clinical operations. Company leaders said the raise will support regulatory filings and partnering discussions as the program approaches the clinic.